JP5539653B2 - 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 - Google Patents
細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 Download PDFInfo
- Publication number
- JP5539653B2 JP5539653B2 JP2008556587A JP2008556587A JP5539653B2 JP 5539653 B2 JP5539653 B2 JP 5539653B2 JP 2008556587 A JP2008556587 A JP 2008556587A JP 2008556587 A JP2008556587 A JP 2008556587A JP 5539653 B2 JP5539653 B2 JP 5539653B2
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- tyrosine kinase
- cells
- treatment
- kinase inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
Description
Fabianら、「A small molecule-kinase interaction map for clinical kinase inhibitors」、Nature Biotechnology 23、329頁
Claims (8)
- チロシンキナーゼ阻害剤での処置に反応した心毒性を予測するための方法であって、
チロシンキナーゼ阻害剤で心筋細胞を処置する段階と、
脂肪酸酸化障害が前記処置された心筋細胞に存在するかどうかを判定する段階とを含み、
それによって、前記処置された心筋細胞の脂肪酸酸化障害の存在により、チロシンキナーゼ阻害剤での心筋細胞の処置が毒性である可能性が高いことが予測される、方法。 - チロシンキナーゼ阻害剤がerbB阻害剤である請求項1に記載の方法。
- チロシンキナーゼ阻害剤がトラスツズマブである請求項1に記載の方法。
- 脂肪酸酸化障害が、チロシンキナーゼ阻害剤での処置による脂肪酸酸化障害の無い細胞中の脂質含量の減少と比較して、チロシンキナーゼ阻害剤での処置による細胞の脂質含量の減少を測定することによって判定される請求項1に記載の方法。
- 脂肪酸酸化障害が、脂肪酸酸化障害の無い細胞と比較して、細胞中の脂肪酸酸化代謝経路における少なくとも1種の酵素活性の減少量を測定することによって判定される請求項1に記載の方法。
- 脂肪酸酸化障害が、脂肪酸酸化障害の無い細胞と比較して、細胞中の脂肪酸酸化代謝経路における少なくとも1種の酵素をコードするmRNAの減少量を測定することによって判定される請求項1に記載の方法。
- 脂肪酸酸化障害が、チロシンキナーゼ阻害剤での正常細胞の処置による細胞中の脂肪酸酸化代謝経路における少なくとも1種の酵素量を測定することによって判定される請求項1に記載の方法。
- 脂肪酸酸化障害が、チロシンキナーゼ阻害剤での正常細胞の処置によるATP量の減少を測定することによって判定される請求項1に記載の方法。
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77709606P | 2006-02-27 | 2006-02-27 | |
US60/777,096 | 2006-02-27 | ||
US82123006P | 2006-08-02 | 2006-08-02 | |
US60/821,230 | 2006-08-02 | ||
US82737206P | 2006-09-28 | 2006-09-28 | |
US60/827,372 | 2006-09-28 | ||
US82834506P | 2006-10-05 | 2006-10-05 | |
US60/828,345 | 2006-10-05 | ||
US86773606P | 2006-11-29 | 2006-11-29 | |
US60/867,736 | 2006-11-29 | ||
PCT/US2007/062871 WO2007101191A2 (en) | 2006-02-27 | 2007-02-27 | Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012282502A Division JP2013063090A (ja) | 2006-02-27 | 2012-12-26 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009533017A JP2009533017A (ja) | 2009-09-17 |
JP5539653B2 true JP5539653B2 (ja) | 2014-07-02 |
Family
ID=38459790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008556587A Expired - Fee Related JP5539653B2 (ja) | 2006-02-27 | 2007-02-27 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
JP2012282502A Pending JP2013063090A (ja) | 2006-02-27 | 2012-12-26 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012282502A Pending JP2013063090A (ja) | 2006-02-27 | 2012-12-26 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8709738B2 (ja) |
EP (1) | EP1996939B1 (ja) |
JP (2) | JP5539653B2 (ja) |
KR (1) | KR101390625B1 (ja) |
CN (2) | CN101438155B (ja) |
AU (1) | AU2007220094B2 (ja) |
CA (1) | CA2643846A1 (ja) |
ES (1) | ES2475162T3 (ja) |
IL (1) | IL193715A (ja) |
NZ (2) | NZ571465A (ja) |
WO (1) | WO2007101191A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
WO2015027171A1 (en) * | 2013-08-23 | 2015-02-26 | Quintiles Transnational Corporation | Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway |
KR102015205B1 (ko) | 2015-02-27 | 2019-08-27 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 리프로그래밍 전구체 조성물 및 그의 사용 방법 |
CA3025344A1 (en) | 2016-05-25 | 2017-11-30 | Salk Institute For Biological Studies | Compositions and methods for organoid generation and disease modeling |
JP7032723B2 (ja) * | 2017-07-21 | 2022-03-09 | 公立大学法人福島県立医科大学 | 薬剤の心毒性評価方法及びそのための試薬又はキット |
EP3710001A4 (en) | 2017-10-27 | 2021-07-14 | University Of Virginia Patent Foundation | COMPOUNDS AND PROCEDURES FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION |
TWI711458B (zh) * | 2019-07-08 | 2020-12-01 | 大江生醫股份有限公司 | 植物發酵物及其製備方法與用於胃臟保健的用途 |
KR102493664B1 (ko) | 2020-01-29 | 2023-02-01 | 한국화학연구원 | 심장 독성 예측 모델링 시스템 및 모델링 방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
DK1438420T3 (da) * | 2001-09-24 | 2010-01-18 | Lipomics Technologies Inc | Fremgangsmåder til anvendelse af kvantitative lipid-metablom-data |
CA2504313C (en) * | 2002-11-04 | 2012-01-17 | Marc K. Hellerstein | Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body |
WO2005021788A1 (en) * | 2003-08-28 | 2005-03-10 | Ipsogen | Identification of an erbb2 gene expression signature in breast cancer |
-
2007
- 2007-02-27 AU AU2007220094A patent/AU2007220094B2/en not_active Ceased
- 2007-02-27 WO PCT/US2007/062871 patent/WO2007101191A2/en active Application Filing
- 2007-02-27 ES ES07757542.1T patent/ES2475162T3/es active Active
- 2007-02-27 EP EP07757542.1A patent/EP1996939B1/en not_active Not-in-force
- 2007-02-27 CN CN2007800136974A patent/CN101438155B/zh not_active Expired - Fee Related
- 2007-02-27 US US12/280,893 patent/US8709738B2/en not_active Expired - Fee Related
- 2007-02-27 KR KR1020087023650A patent/KR101390625B1/ko not_active IP Right Cessation
- 2007-02-27 JP JP2008556587A patent/JP5539653B2/ja not_active Expired - Fee Related
- 2007-02-27 NZ NZ571465A patent/NZ571465A/en not_active IP Right Cessation
- 2007-02-27 CA CA002643846A patent/CA2643846A1/en not_active Abandoned
- 2007-02-27 NZ NZ594178A patent/NZ594178A/xx not_active IP Right Cessation
- 2007-02-27 CN CN2013101368247A patent/CN103217520A/zh active Pending
-
2008
- 2008-08-26 IL IL193715A patent/IL193715A/en not_active IP Right Cessation
-
2012
- 2012-12-26 JP JP2012282502A patent/JP2013063090A/ja active Pending
-
2013
- 2013-04-05 US US13/857,591 patent/US20130288285A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20090008194A (ko) | 2009-01-21 |
JP2013063090A (ja) | 2013-04-11 |
CA2643846A1 (en) | 2007-09-07 |
ES2475162T3 (es) | 2014-07-10 |
NZ571465A (en) | 2011-09-30 |
EP1996939A4 (en) | 2009-07-15 |
NZ594178A (en) | 2013-02-22 |
US8709738B2 (en) | 2014-04-29 |
AU2007220094A1 (en) | 2007-09-07 |
EP1996939B1 (en) | 2014-03-26 |
WO2007101191A2 (en) | 2007-09-07 |
CN101438155A (zh) | 2009-05-20 |
KR101390625B1 (ko) | 2014-04-29 |
US20130288285A1 (en) | 2013-10-31 |
CN101438155B (zh) | 2013-04-24 |
JP2009533017A (ja) | 2009-09-17 |
US20090186910A1 (en) | 2009-07-23 |
AU2007220094B2 (en) | 2013-12-05 |
IL193715A (en) | 2014-06-30 |
EP1996939A2 (en) | 2008-12-03 |
CN103217520A (zh) | 2013-07-24 |
WO2007101191A3 (en) | 2007-12-13 |
IL193715A0 (en) | 2009-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013063090A (ja) | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 | |
JP7256165B2 (ja) | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 | |
Odaira et al. | Mechanisms underpinning AMP-activated protein kinase-related effects on behavior and hippocampal neurogenesis in an animal model of depression | |
Hayot et al. | Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli | |
Ishikura et al. | Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells | |
WO2008016730A2 (en) | Compositions and methods for reducing cellular fat | |
Lenski et al. | Arrhythmia causes lipid accumulation and reduced glucose uptake | |
US20100048944A1 (en) | Interactions of hedgehog and liver x receptor signaling pathways | |
Wu et al. | Targeting hepatic pyruvate dehydrogenase kinases restores insulin signaling and mitigates ChREBP-mediated lipogenesis in diet-induced obese mice | |
Zou et al. | C/EBPβ knockdown protects cardiomyocytes from hypertrophy via inhibition of p65-NFκB | |
Wilson et al. | Pyruvate induces mitochondrial biogenesis by a PGC-1 α-independent mechanism | |
Zhong et al. | β-hydroxy-β-methylbutyrate (HMB) improves mitochondrial function in myocytes through pathways involving PPARβ/δ and CDK4 | |
Cai et al. | Deficiency of telomere-associated repressor activator protein 1 precipitates cardiac aging in mice via p53/PPARα signaling | |
US7915255B2 (en) | Metabolism-modulating agents and uses therefor | |
Koshman et al. | Signaling responses after exposure to 5α-dihydrotestosterone or 17β-estradiol in norepinephrine-induced hypertrophy of neonatal rat ventricular myocytes | |
Jung et al. | IPMK modulates insulin-mediated suppression of hepatic glucose production | |
US20230190689A1 (en) | Methods and compositions for inducing brown adipogenesis | |
JP2018535247A (ja) | 運動類似効果誘導用薬学組成物 | |
Rector | Fibroblast Growth Factor 21 and Exercise-Induced Hepatic Mitochondrial Adaptations 1 2 Justin A. Fletcher1, 3, Melissa A. Linden1, 3, Ryan D. Sheldon1, 3, Grace M. Meers2, 3, E. Matthew 3 Morris5, Anthony Butterfield4, James W. Perfield II4, John P. Thyfault5, 6, and R. Scott Rector1, 2, 3 4 5 | |
Koshman et al. | Articles in PresS. J Appl Physiol (December 31, 2009). doi: 10.1152/japplphysiol. 00994.2009 | |
Khalid | The Relationship Between Insulin Resistance and Hyperinsulinemia on Mammary Cancer Growth and Development | |
TW201422226A (zh) | PPARα活化劑增加ATGL蛋白表現及減少脂肪堆積之用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120626 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120920 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130423 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130722 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130729 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140401 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5539653 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140501 |
|
LAPS | Cancellation because of no payment of annual fees |